Skip to content

Ayurvedic Management to reduce the disturbance of seeing black spots in front of the visual field.

Clinical outcomes of oral administration of Ayurvedic polyherbal formulation (Mahatriphala ghrita) for 90 days compared to the baseline in patients( 50-70 years) with Vitreous floaters at a research hospital in Kerala: A case series - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/11/097141
Enrollment
10
Registered
2025-11-10
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H433- Other vitreous opacities

Interventions

Intervention1: Nil: Nil

Sponsors

Central Council for Research in Ayurvedic Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants presenting with symptomatic vitreous floaters persisting for more than three months. They should have a clear ocular media to allow a clear view of the vitreous.

Exclusion criteria

Exclusion criteria: Presence of vitreous hemorrhage, asteroid hyalosis Opacification of lens, cornea or vitreous. Retinal diseases (e.g., Pathological myopia, retinal breaks or detachments, age-related macular degeneration, diabetic retinopathy, and branch retinal vein occlusion) Patients with Aspartate Amino Transferase (AST) and or Alanine Amino Transferase (ALT) levels greater than 2 times the upper normal limit, or Patients with S. Creatinine greater than the upper limits of the normal. History of malignancy within five years. History of hypersensitivity to the trial drug or any of its ingredients. Continuing addiction to smoking and usage of tobacco in any form Individuals simultaneously or previously (within 30 days before the investigation starts) participated in a clinical investigation using experimental drugs or devices.

Design outcomes

Primary

MeasureTime frame
The average change from baseline in the Floater Disturbance Questionnaire score compared to baseline at the end of 90 days.Timepoint: The average change from baseline in the Floater Disturbance Questionnaire score compared to baseline at the end of 90 days.

Secondary

MeasureTime frame
The average change from baseline in the NEI VFQ-25 score compared to baseline at the end of 90 days.Timepoint: 90 days;The average changes from baseline in the LFT and KFT, values compared to baseline at the end of 90 days. Timepoint: 90 days;Participant-reported adherence, defined as taking or not taking study medication. Timepoint: 90 days

Countries

India

Contacts

Public ContactKrishna Kumar V

National Ayurveda Research Institute fort Panchakrma , Cheruthuruthy

drkkempran@gmail.com07306892140

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026